Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H. DiNubile MJ, et al. Among authors: teppler h. Antimicrob Agents Chemother. 2005 Aug;49(8):3217-21. doi: 10.1128/AAC.49.8.3217-3221.2005. Antimicrob Agents Chemother. 2005. PMID: 16048928 Free PMC article. Clinical Trial.
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).
Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, Snyder TA, Harvey CM, Teppler H, Dinubile MJ, Chow JW. Paterson DL, et al. Among authors: teppler h. J Antimicrob Chemother. 2005 Jun;55(6):965-73. doi: 10.1093/jac/dki117. Epub 2005 Apr 22. J Antimicrob Chemother. 2005. PMID: 15849262
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H; Protocol 017 Study Group. Solomkin JS, et al. Among authors: teppler h. Ann Surg. 2003 Feb;237(2):235-45. doi: 10.1097/01.SLA.0000048551.32606.73. Ann Surg. 2003. PMID: 12560782 Free PMC article. Clinical Trial.
Safety and tolerability of ertapenem.
Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R. Teppler H, et al. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii75-81. doi: 10.1093/jac/dkh209. J Antimicrob Chemother. 2004. PMID: 15150186 Review.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Steigbigel RT, et al. Among authors: teppler h. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975. N Engl J Med. 2008. PMID: 18650512 Free article. Clinical Trial.
77 results